Days after poaching a health system executive to pull together its disparate healthcare ventures, Google moved to reabsorb DeepMind’s health business, including those behind its mobile app for doctors and nurses.
DeepMind, Alphabet’s U.K.-based artificial intelligence company, announced in a blog post that the team responsible for its Streams app and medical research projects will be joining the tech giant. Google first acquired DeepMind in 2014, before restructuring into its parent company, Alphabet, and transferring its subsidiaries.
Since then, DeepMind’s health researchers have explored the use of AI in reading mammograms and head and neck CT scans, as well as mining historical health records from the U.S. Department of Veterans Affairs for patterns to predict the deterioration of patients while under care.
The Streams app, meanwhile, is used to automatically review test results for potentially serious issues, alert the patient’s relevant clinicians, and provide them information on previous conditions to assist in diagnosis.
The end game is for Streams to become “an AI-powered assistant for nurses and doctors everywhere,” combining its algorithms with strong evidence, DeepMind wrote, with the project being completed from within Google.
The DeepMind health team will remain in London and will continue its work with its academic and National Health Service partners, the company said. In the future, it will work with Google to incorporate the results of its research into clinical settings.
Last week, Google hired Geisinger CEO David Feinberg, M.D., to develop a cohesive strategy for Google’s various health and health-adjacent enterprises, including through home automation hardware and wearables.
During Feinberg’s four-year tenure at Geisinger—which services more than 1.5 million patients—the health system pursued several programs to integrate big data, electronic health records and genomics into its care, including through collaborations with pharmaceutical companies.
By Conor Hale
Source: Fierce Biotech
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
